Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

 (Original) An imidazotriazinone compound represented by the following formula (IA) or (IB):

wherein

A is N or CR4:

B is N or CH:

R1 is substituted or unsubstituted cycloalkyl group or tert-butyl group;

R2 is a hydrogen atom or C1-C6 alkyl group;

R³ is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C₁-C₆ alkyl group; substituted or unsubstituted C₂-C₆ alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: -NR⁵R⁶, -C(O)R⁷, -SO₂R⁷, -OR⁸, -NR⁸COR⁷, -NR⁸SO₂R⁷;

 R^4 is a hydrogen atom or C_1 - C_3 alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s):

 R^5 and R^6 are, same or different from each other, a hydrogen atom; substituted or unsubstituted C_1 - C_6 alkyl group; substituted or unsubstituted acyl group; or substituted or unsubstituted heterocycloalkyl group;

R⁷ is a hydrogen atom; substituted or unsubstituted C₁-C₆ alkyl group; substituted or unsubstituted heterocycloalkyl group; OH; -OR⁸ or -NR⁵R⁶;

 R^8 is a hydrogen atom, substituted or unsubstituted C_1 - C_6 alkyl group; or substituted or unsubstituted heterocycloalkyl group; or pharmaceutically acceptable salts or solvates thereof

2. (Original) The compound represented by the formula (IA) according to claim 1.

PATENT APPLICATION No. 10/560,503 ATTORNEY DOCKET: 69681,000006

- 3. (Withdrawn) The compound represented by the formula (IB) according to claim 1.
- (Original) The compound according to claim 1, in which R¹ is substituted or unsubstituted C₃-C₈ cycloalkyl group.
- (Previously Presented) The compound according to claim 4, in which R¹ is cyclopentyl, cyclohexyl or cycloheptyl.
- (Previously Presented) The compound according to claim 1, in which A is CR⁴ wherein R⁴
 is methoxy or ethoxy group.
- 7. (Previously Presented) The compound according to claim 1, in which B is CH.
- 8. (Previously Presented) The compound according to claim 1, in which R² is methyl group.
- (Previously Presented) The compound according to claim 1, in which R³ is a hydrogen atom; a halogen atom; saturated or unsaturated heterocycloalkyl group; an -NR⁵R⁶, -C(O)R³, or -SO₂R³ group, wherein R³ is OH, -OR⁶, -NR⁵R⁶ or a substituted or unsubstituted heterocycloalkyl group.
- (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1, or pharmaceutically acceptable salts or solvates thereof as active ingredient.
- (Previously Presented) A PDE 7 inhibitor comprising a compound according to claim 1, or pharmaceutically acceptable salts or solvates thereof as active ingredient.